Abstract
Recent studies suggest even low dosages of oestrogen currently used for treatment of prostate cancer increase cardiovascular morbidity. In addition, relapse following growth of hormone-insensitive cells, and the present observations of further evidence of immunosuppression demonstrated by the significant (p < 0.001) effect of DES on the lytic activity of natural killer cells vs. the negligible effect of the luteinizing - hormone - releasing - hormone, leuprolide (Lupron) raises concern that the palliative effects of oestrogen therapy are possibly further compromised by a reduction in immunosurveillance to tumour, or equally important, by a decreased capacity to cope with infectious agents.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 73-76 |
| Number of pages | 4 |
| Journal | Anticancer research |
| Volume | 8 |
| Issue number | 1 |
| State | Published - 1988 |
| Externally published | Yes |
ASJC Scopus subject areas
- Oncology
- Cancer Research